Background: Community pharmacies play a key role in the care of patients when dispensing antiretroviral therapy.
Antiretroviral therapy (ART) has revolutionized the treatment of HIV infection since its widespread introduction in 1996. 1 Community pharmacies can play a key role when dispensing these life-extending medications. In an ideal model, pharmacists build trusted relationships with patients, provide medication counseling, monitor safety and efficacy of antiretroviral regimens, and reinforce treatment adherence. 2,3 Within this ideal model, patients view visits to their pharmacy as an important part of their health care.
Pharmacists often encourage HIV-positive patients to have a community pharmacy "home," where they keep all of their prescriptions. This is because HIV-positive patients may require care from several different clinicians-for example, a primary care provider, an HIV specialist, a cardiologist, a hepatologist-who may not have linked medical records and may not be aware what the other clinicians are prescribing. If such patients were to use multiple pharmacies, they may be at risk for significant drug interactions, additive adverse effects, or duplicate therapies. Most major community pharmacy chains have integrated computer systems that effectively allow a patient's record to be accessed by any pharmacist within the chain, but not all pharmacies are linked in that manner. The primary objective of this study was to describe patterns of community pharmacy use, including the types and number used, by women enrolled in the San Francisco site of the Women's Interagency HIV Study (WIHS). The secondary objectives were to determine what factors are associated with using multiple dispensing pharmacies, and whether this behavior is associated with immunologic and virologic outcomes in HIV-positive women.
Methods
The WIHS is a multicenter, longitudinal, observational, prospective cohort study of the natural history of HIV infection in US women. Data are collected at 6 study sites (Los Angeles, San Francisco, Chicago, Bronx, Brooklyn, Washington DC) and 1 data coordinating center (Baltimore) from HIV-positive women and HIV-negative women at risk for acquiring HIV infection. Participants are interviewed at semiannual visits. A variety of laboratory, clinical, demographic, and psychosocial assessments are performed. 4,5 CD4+ cell count and HIV-RNA are measured, using standard techniques at laboratories that participate in National Institutes of Health/National Institute of Allergies and Infectious Diseases quality assurance programs. The WIHS does not provide clinical care; therefore, all medications are prescribed by the participant's own clinician.
A brief survey form documenting community pharmacy use was instituted for the San Francisco WIHS site.
Participants were asked to fill out this form at each WIHS study visit that occurred between 2004 and 2007. Any woman who self-reported taking medications for any chronic disease and who filled out at least one pharmacy survey during the study period was included in the analysis. Approval for this study was obtained from the University of California San Francisco Institutional Review Board.
OUTCOMES OF INTEREST
The primary outcome of interest was the number of community pharmacies that a participant reported using. In the community pharmacy survey form, participants filled in names and addresses of each pharmacy that they had used to obtain any prescription medications since the last WIHS study visit. These forms were used to calculate the number of different pharmacies reported by each individual. Pharmacy names and addresses were clarified using the Internet and by telephone calls when a telephone number was available. If a pharmacy's name could not be discerned from the survey form, it was labeled "pharmacy unknown." For chain and independent pharmacies with multiple store locations, each location reported was counted as a separate pharmacy. If the participant reported the name of a pharmacy that has multiple store locations, but the exact store used could not be determined, it was categorized as "pharmacy name, city, unknown." If a patient had multiple "unknown" pharmacy entries over the 3-year study period, only the first unknown of its type was counted. The rest were assumed to be duplicates (eg, if a patient reported using "chain pharmacy, unknown location" every year for 3 years, this was counted as 1 pharmacy rather than 3 different pharmacies). We chose to count only the first unknown pharmacy because this would result in obtaining a conservative estimate of the different pharmacies that a participant used, rather than overestimating the unknowns. Pharmacies were classified as chain, hospital/clinic-associated, independent, or unknown pharmacies based on prior investigator knowledge and telephone calls made to the pharmacies for clarification.
For the subgroup of HIV-positive patients taking antiretrovirals, we wanted to assess the association (if any) between changes in CD4+ cell counts and HIV viral loads and use of multiple dispensing pharmacies. Baseline CD4+ cell counts and HIV viral loads were measured at the first study visit that a community pharmacy survey was completed. These were compared with subsequent measurements taken at additional study visits at which the community pharmacy survey forms were filled out.
COVARIATES
Data routinely collected at WIHS study visits were included in the analyses. Race was measured by self-report upon initial enrollment into WIHS. Participants' reported highest educational attainment, annual household income, marital status, sexual identity, place of residence, health insurance, employment status, drug and alcohol use in the past 6 months, presence of depressive symptoms (Center for Epidemiologic Studies Depression Score ≥16), or other presence of comorbid conditions were obtained at the first study visit during which the community pharmacy survey was completed. HIV-specific data included HIV status, whether a participant had an AIDS diagnosis, and the study date that she reported first taking ART. Baseline CD4+ cell count and HIV viral load were measured at the first study visit during which a participant filled out a community pharmacy use survey and were measured at each subsequent study visit.
STATISTICAL ANALYSIS
Repeated measures Poisson regression was used to assess the association between various patient characteristics and the number of pharmacies at each study visit. Covariates included for face validity in the multivariable model were HIV status, race, education, residence, employment, income, drug and alcohol use, hypertension,
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The primary outcome of interest was the number of community pharmacies that a participant reported using.
w diabetes, hyperlipidemia, depression score, and study visit number. A backwards selection process including variables with a p value of ≤0.2 was used to determine the most parsimonious model for the multivariate analysis of characteristics associated with multiple pharmacy use. Repeated-measures linear and logistic regression methods, using generalized estimating equations, were used to assess the relationship between the number of pharmacies and changes in CD4+ cell count or viral load. Models were adjusted for adherence, employment, insurance, depression score, AIDS, number of years taking antiretrovirals, number of antiretrovirals taken, type of pharmacy use, and visit number. All analyses were performed using STATA version 10.0 (StataCorp, College Station, TX).
Results
Six WIHS study visits occurred between 2004 and 2007 for 352 participants. On average, each participant filled out a median of 5 pharmacy surveys (SD 1.38) and was followed for an average of 2.2 person years (95% CI 2.06 to 2.25). At least 300 unique pharmacy stores were frequented by the participants. There were 14 entries in which the pharmacy name could not be determined from the survey form (unknown). There were 163 entries in which the pharmacy name was determined but its exact location was not (pharmacy name, city, unknown). Women reported using an average of 2.7 (SD 1.5, range 1-7) pharmacies over the 2004-2007 study period (Table 1) . Most (64%) women identified 1 pharmacy that they were primarily using over the past 6-month study period. The most common types of pharmacies reported by participants were chain pharmacies (68%), hospital-or clinic-associated pharmacies (43%), and independent pharmacies (46%).
To determine what factors were associated with using multiple dispensing pharmacies, characteristics of the 352 participants were analyzed. The majority of participants were HIV positive, African American, of low-income background, and had comorbidities such as diabetes, hypertension, and hyperlipidemia ( Table 2 ). In univariate analyses, HIV-positive status was the only factor associated with use of more than 1 pharmacy over the study period (IRR 1.24; 95% CI 1.01 to 1.53; p = 0.04). This association was no longer statistically significant when adjusted for employment in the multivariable analysis (IRR 1.23; 95% CI 1.00 to 1.51; p = 0.05). Among HIV-positive women on ART, using multiple pharmacies was associated with a nonstatistically significant 5% decrease (95% CI 11% to 2%; p = 0.13) in mean CD4+ count for each additional pharmacy used, over the primary pharmacy, after adjustment of other factors that may influence CD4+ cell count rise or decline. Using multiple pharmacies over the study period was not associated with a higher likelihood of having a detectable viral load (adjusted OR 1.19; 95% CI 0.96 to 1.48; p = 0.12).
Discussion
Clinicians may take for granted that the seemingly simple task of acquiring medications from a pharmacy may require a certain level of organizational skill. However, the use of multiple pharmacies is usually not favored by clinicians. When multiple pharmacies are involved, it can make reconciling a patient's home medications more difficult. This is especially true when a patient uses pharmacies that do not have linked pharmacy records-for example, if a patient were to obtain HIV medicines at an independent specialty pharmacy but other routine medications at a local chain pharmacy. In addition, patients who are disorganized may find it difficult to keep track of and remember to obtain and take all of their medications on time if they fill them at multiple pharmacies. Our study found that HIV-positive women used multiple pharmacies more often compared with their HIV-negative counterparts, although the association was not statistically significant when adjusted for employment. A study in elderly Department of Defense beneficiaries found that having greater than 10 medications was associated with the behavior of using multiple dispensing pharmacies (adjusted OR 8.43; 95% CI 8.21 to 8.65). 6 In our study, having a chronic condition such as diabetes, hypertension, or hyperlipidemia was not associated with using multiple pharmacies even though treatment of these conditions also often involves taking multiple medications. It is possible that antiretrovirals are not routinely stocked in all pharmacies, requiring HIV-positive patients to use more than 1 pharmacy to obtain all necessary medications. Employed patients may choose to frequent a pharmacy near their workplace as well as one near their home for convenience.
Despite the negative impressions attributed to using multiple dispensing pharmacies, our study found that this behavior was not associated with poorer HIV treatment outcomes. Few published studies have looked at the number of pharmacies that patients use and how that impacts treatment outcomes. One Canadian study found that use of a single dispensing pharmacy lowered the risk of inappropriate drug combinations in elderly patients (OR 0.68; 99% CI 0.6 to 0.8). 7 Based on this, pharmacists caring for HIV-positive patients should inquire as to whether they are obtaining medicines elsewhere and should communicate with the patient's other pharmacists and health-care providers to lower the risk of drug interactions. Further studies are needed to affirm whether using multiple dispensing pharmacies (or having other pharmacy utilization patterns) can impact HIV treatment outcomes. Not only the number, but also the type of pharmacy a patient chooses may predict HIV treatment outcomes; in one study, patients who used a hospital-associated pharmacy had higher refill adherence to ART. 8 Future studies should also look at whether HIV specialty pharmacies versus traditional community pharmacies or increasing the distance a patient must travel to arrive at a pharmacy may make a difference in adherence or treatment outcomes.
The limitations of our study included the retrospective, self-reported nature of pharmacy use. This could have introduced recall bias that underrepresented the true number of pharmacies a participant used during the study period. Due to the nature of the data collection, certain assumptions were made during the counting and categorizing of pharmacies (eg, pharmacy unknown), which may have also underestimated the number of pharmacies used. HIV-negative women in the WIHS study are at risk for acquiring HIV infection; therefore, their group may not be generalizable to other HIV seronegative women in the US. Lastly, this study was conducted in the San Francisco Bay Area, which has a high density of HIV-positive patients and pharmacies; therefore, the results may not be generalizable to HIV communities in other locations. HIV-positive participants in our study trended toward a higher risk of using more than 1 pharmacy to obtain prescription medications. Pharmacists should inquire about multiple pharmacy usage to lower the chances of drug interactions and duplicate therapies for their HIVpositive patients. However, an HIV-positive participant's self-reported use of multiple dispensing community pharmacies was not associated with lower CD4+ cell counts or a detectable viral load. Future research on patterns of community pharmacy use in HIV-positive patients will be useful in establishing HIV-specific community pharmacy programs, can inform clinicians as to the optimal use of pharmacies to dispense antiretrovirals, and can provide a rationale for establishing pharmacies in areas with a higher density of HIV-positive patients.
